US2014087000A1PendingUtilityA1

Method and System for Treatment of Biological Tissue

65
Assignee: MATHENY ROBERT GPriority: Jan 18, 2006Filed: May 1, 2013Published: Mar 27, 2014
Est. expiryJan 18, 2026(expired)· nominal 20-yr term from priority
Inventors:Robert G. Matheny
A61K 31/47A61K 31/40A61L 27/367A61K 31/22A61L 2400/06A61L 27/3633A61K 48/00A61K 45/06A61K 31/65A61B 17/205A61K 31/505A61K 31/366A61K 38/14A61K 31/4418A61P 9/00A61L 27/3873A61K 31/43A61K 31/7048A61K 31/722A61L 2430/20A61P 9/10A61P 43/00A61K 9/0019A61K 35/38A61L 27/3683A61K 31/4174A61K 31/404A61K 35/34A61K 31/7056A61B 2017/00247A61K 31/165A61L 27/3834A61L 27/3804
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An injectable composition for treating damaged cardiovascular tissue, comprising:
 an extracellular matrix (ECM) component and a supplemental drug component, said ECM component comprising mammalian tissue, said drug component comprising an antibiotic, said mammalian tissue comprising decellularized cardiac tissue.   
     
     
         2 . The composition of  claim 1 , wherein said antibiotic is selected from the group consisting of aminoglycosides, cephalosporins, chloramphenicol, clindamycin, erythromycins, fluoroquinolones, macrolides, azolides, metronidazole, penicillins, tetracyclines, trimethoprim-sulfamethoxazole and vancomycin.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.